Literature DB >> 12690022

Mortality of hepatitis B surface antigen-positive blood donors in England and Wales.

Paul D Crook1, Michael E Jones, Andrew J Hall.   

Abstract

BACKGROUND: Large population-based cohort studies in areas of high hepatitis B virus (HBV) prevalence have provided the evidence establishing hepatitis B surface antigen (HBsAg) carriage as a risk factor for hepatocellular carcinoma (HCC) and liver disease. Fewer studies have examined this in Western countries, where both HBV infection and carriage are less common and transmission patterns differ. This is the only prospective population-based study to examine this relationship in Europe.
METHODS: In all, 2681 male and 977 female blood donors in England and Wales, found to be HBsAg positive during routine blood-donation screening, were followed up from recruitment in 1970-1982 to December 1999 and their cause-specific mortality was analysed. This was compared with that of the general population of England and Wales.
RESULTS: During a mean of 22 years of follow-up, 17.4% of the 420 deaths were due to HCC or liver disease. There were 20 deaths from HCC in male HBsAg carriers, representing a significantly high standardized mortality ratio (SMR) compared to the male population of England and Wales of 26 (SMR = 26.26; 95% CI: 16.04- 40.54). The HCC incidence rate in males was 33.5 per 100 000 person years and 4.4 per 100 000 person years in females. Men had 8.5 (SMR = 8.50; 95% CI: 6.25- 11.31) and women had 3.9 times the risk of death from liver disease (SMR = 3.89; 95% CI: 1.26-9.09). The risk of circulatory disease deaths was reduced in both males and females. There was a significant increased risk of non-Hodgkins lymphoma that was not apparent in the first decade of follow-up. The increased risk of HCC and liver disease in men fell with follow-up.
CONCLUSION: Hepatitis B surface antigen carriage is a significant risk factor in England and Wales for both liver disease and HCC mortality. However, this risk has declined with duration of follow-up. This could be due to natural reversion to HBsAg negativity or as a result of treatment and avoidance of other risk factors. The increased risk of non-Hodgkins lymphoma seen in longer follow-up is likely to be related to HIV infection acquired subsequent to recruitment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12690022     DOI: 10.1093/ije/dyg039

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


  14 in total

1.  Cost-effectiveness analysis of prophylactic lamivudine use in preventing vertical transmission of hepatitis B virus infection.

Authors:  Hui-Fang Hung; Hsiu-Hsi Chen
Journal:  Pharmacoeconomics       Date:  2011-12       Impact factor: 4.981

2.  Risk of malignant lymphoma following viral hepatitis infection.

Authors:  Pierluigi Cocco; Giovanna Piras; Maria Monne; Antonella Uras; Attilio Gabbas; Maria G Ennas; Angelo Palmas; Marco Murineddu; Stefania Collu; Massimo Melis; Marco Rais; Pierfelice Todde; Maria G Cabras; Emanuele Angelucci; Giovannino Massarelli; Alexandra Nieters
Journal:  Int J Hematol       Date:  2008-05-01       Impact factor: 2.490

3.  The association of hepatitis B virus infection with B-cell non-Hodgkin lymphoma - a review.

Authors:  Fabrizio Marcucci; Enea Spada; Alfonso Mele; Carmelo Antonio Caserta; Alessandro Pulsoni
Journal:  Am J Blood Res       Date:  2012-01-01

4.  Increased age, male gender, and cirrhosis, but not steatosis or a positive viral serology, negatively impact the life expectancy of patients who undergo liver biopsy.

Authors:  Mitchell S Wachtel; Yan Zhang; Kim E Kaye; Maurizio Chiriva-Internati; Eldo E Frezza
Journal:  Dig Dis Sci       Date:  2007-04-04       Impact factor: 3.199

5.  Occupation and mortality related to alcohol, drugs and sexual habits.

Authors:  D Coggon; E C Harris; T Brown; S Rice; K T Palmer
Journal:  Occup Med (Lond)       Date:  2010-04-20       Impact factor: 1.611

Review 6.  Nucleos(t)ide analogs in the prevention of hepatitis B virus related hepatocellular carcinoma.

Authors:  Bulent Baran
Journal:  World J Hepatol       Date:  2015-07-08

7.  HBsAg is an independent prognostic factor in diffuse large B cell lymphoma patients in rituximab era: result from a multicenter retrospective analysis in China.

Authors:  Zheng Wei; Shanhua Zou; Feng Li; Zhixiang Cheng; Junmin Li; Jianmin Wang; Chun Wang; Fangyuan Chen; Junning Cao; Yunfeng Cheng
Journal:  Med Oncol       Date:  2014-01-28       Impact factor: 3.064

Review 8.  Association between infection of hepatitis B virus and onset risk of B-cell non-Hodgkin's lymphoma: a systematic review and a meta-analysis.

Authors:  Hai-zhen Yi; Jin-jing Chen; Hong Cen; Wei Yan; Xiao-hong Tan
Journal:  Med Oncol       Date:  2014-06-28       Impact factor: 3.064

9.  Epidemiologic study of chronic hepatitis B virus infection in male volunteer blood donors in Karachi, Pakistan.

Authors:  Saeed Akhtar; Muhammad Younus; Salman Adil; Farrukh Hassan; Sarffraz Hussain Jafri
Journal:  BMC Gastroenterol       Date:  2005-08-08       Impact factor: 3.067

10.  Hepatitis B virus genotype distribution and genotype-specific BCP/preCore substitutions in acute and chronic infections in Argentina.

Authors:  María Mora González López Ledesma; Laura Noelia Mojsiejczuk; Belén Rodrigo; Ina Sevic; Lilia Mammana; Omar Galdame; Adrian Gadano; Hugo Fainboim; Rodolfo Campos; Diego Flichman
Journal:  PLoS One       Date:  2015-03-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.